🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Adult T-Cell Leukemia/Lymphoma (ATLL)

Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients NCT07313592n/a1 site📍 St Louis Washington University School of Medicine Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL) NCT04301076Phase 119 sites📍 Atlanta📍 Atlanta📍 City of Saint Peters National Cancer Institute (NCI) · Tests: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma NCT07075328Phase 1, Phase 25 sites📍 Fukuoka📍 Sapporo📍 Kagoshima Otsuka Medical Devices Co., Ltd. Japan · Tests: Drug:5-ALA, Device:Photodynamic system A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy) NCT06561074Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Decitabine, Venetoclax, Calaspargase pegol-mknl SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies NCT07153068Phase 1, Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: supCD7 CART cells Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells NCT06420076Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: CD5/CD7 CAR-T Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer NCT01137643n/a1 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: biologic sample preservation procedure, cytology specimen collection procedure Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma NCT06934382Phase 11 site📍 Philadelphia Stephan Grupp MD PhD · Tests: Allogeneic anti-CD7 CAR-T cells (BEAM-201) Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies NCT06909474Phase 11 site📍 Wuhan Chongqing Precision Biotech Co., Ltd · Tests: Anti-CD5 CAR NK cells Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL NCT06874946Phase 1, Phase 21 site📍 Beijing Peking University People's Hospital · Tests: CD5-targeted CAR-T cells Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL NCT05626400NA1 site📍 Beijingcun Hebei Senlang Biotechnology Inc., Ltd. · Tests: Senl-T7 CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) NCT04318678Phase 12 sites📍 Memphis📍 Memphis St. Jude Children's Research Hospital · Tests: CD123-CAR T, Cyclophosphamide, Fludarabine, Mesna, Rituximab Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma NCT05996185Phase 22 sites📍 New Haven📍 New York Yale University · Tests: Mogamulizumab, DA-EPOCH Protocol, CHOEP protocol Registry of Older Patients With Cancer NCT01137825n/a7 sites📍 Boone📍 Chapel Hill📍 Greenville UNC Lineberger Comprehensive Cancer Center A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) NCT06207123Phase 1, Phase 22 sites📍 Chicago📍 Rochester University of Chicago · Tests: LP-118, Ponatinib, Vincristine, Dexamethasone, Methotrexate Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma NCT00501826Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Mercaptopurine Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL NCT05679895Phase 12 sites📍 Barcelona📍 Barcelona OneChain Immunotherapeutics · Tests: CD1a-CAR T Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment NCT01087333n/a1 site📍 Bethesda National Cancer Institute (NCI) CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL NCT06064903Phase 1, Phase 21 site📍 Rome Bambino Gesù Hospital and Research Institute · Tests: CD7-CART01 A Registry for People With T-cell Lymphoma NCT05978141n/a26 sites📍 Duarte📍 San Diego📍 San Francisco Memorial Sloan Kettering Cancer Center · Tests: Optional Blood Sample and Nail Sample uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies NCT07109518Phase 11 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: uCD7 CART Two Step Haplo With Radiation Conditioning NCT05031897Phase 21 site📍 Philadephia Thomas Jefferson University · Tests: Fludarabine, Total-Body Irradiation, Donor Lymphocyte Infusion, Cyclophosphamide, Tacrolimus VHAG in Treating R/R T-ALL/LBL NCT06742463Phase 21 site📍 Hangzhou First Affiliated Hospital of Zhejiang University · Tests: Venetoclax, homoharringtonine, Cytarabine (Ara-C), G-CSF Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL NCT05289687Phase 21 site📍 Chicago Eastern Cooperative Oncology Group · Tests: Daratumumab / Hyaluronidase Injection, Daratumumab / Hyaluronidase Injection, Daratumumab / Hyaluronidase Injection, Da… Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL NCT07203352Phase 31 site📍 Guangzhou Nanfang Hospital, Southern Medical University · Tests: targeted drug Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL). NCT07471789Phase 1, Phase 22 sites📍 Barcelona📍 Valencia Gyala Therapeutics · Tests: CART84 Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma NCT04848064Phase 11 site📍 Columbus John Reneau · Tests: Cyclophosphamide, Fludarabine, Mogamulizumab, Natural Killer Cell Therapy, Quality-of-Life Assessment A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1 NCT06698003Phase 27 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: Mogamulizumab CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study NCT06136364Phase 11 site📍 Shanghai Hebei Senlang Biotechnology Inc., Ltd. · Tests: CAR-T Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients NCT06381817Phase 31 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: Haplo-cord HCT, Haplo-HCT
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy